$ACOR
Acorda Therapeutics Inc
PRICE
$0.515 ▼-7.14%
Last Close
VOLUME
359,188
DAY RANGE
0.49 - 0.6
52 WEEK
0.49 - 6.36
Key Metrics
Market Cap
4.88 M
Beta
1.36
Avg. Volume
163.24 K
Shares Outstanding
13.29 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
CEO: Ron Cohen
Website: www.acorda.com
HQ: 420 Saw Mill River Rd Ardsley, 10502-2605 New York
Related News